Differentiating clinical AD with and without SYN co-pathology using CSF biomarkers is more challenging; however, some studies suggest CSF alpha-synuclein levels may improve diagnostic accuracy [105,108]. This evidence concerns the gene SNCA and Alzheimer disease.